Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 3. Idiopathic Nonspecific Interstitial Pneumonia
Jongmin Lee, Yong Hyun Kim, Ji Young Kang, Yangjin Jegal, So Young Park,
Tuberc Respir Dis. 2019;82(4):277-284.   Published online 2019 May 31     DOI: https://doi.org/10.4046/trd.2018.0092
Citations to this article as recorded by Crossref logo
The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease
Rossella Talotta
Immunotherapy.2021; 13(3): 241.     CrossRef
TPMT and HLA-DQA1-HLA-DRB genetic profiling to guide the use of azathioprine in the treatment of interstitial lung disease: First experience
Nada Taha, Karishma Hosein, Amanda Grant-Orser, Ammy Lin-Shaw, Marco Mura
Pulmonary Pharmacology & Therapeutics.2021; 66: 101988.     CrossRef
Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
Won-Il Choi
Precision and Future Medicine.2021; 5(1): 31.     CrossRef
Acute interstitial pneumonia triggered by strenuous exercise
Frosina Markoska, David Lestan, Matjaz Turel, Matevz Harlander
Respiratory Medicine Case Reports.2020; 30: 101077.     CrossRef
Effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function and serum TNF-β1 and MMP-7 in silicosis patients
Jing Zhang, Yingchun Wang, Shujuan Zhang, Jing Li, Hong Fang
Experimental and Therapeutic Medicine.2020;[Epub]     CrossRef